Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052)-Reference-Cited by-同舟云学术

Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052)

Published:2022 Issue:4 Volume:33 Page:
ISSN:2005-0380
Container-title:Journal of Gynecologic Oncology
language:en
Short-container-title:J Gynecol Oncol

Author:

Asano Hiroshi¹^ORCID,Oda Katsutoshi²^ORCID,Yoshihara Kosuke³^ORCID,Ito Yoichi M⁴^ORCID,Matsumura Noriomi⁵^ORCID,Shimada Muneaki⁶^ORCID,Watari Hidemichi¹^ORCID,Enomoto Takayuki³^ORCID

Affiliation:

1. Department of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

2. Division of Integrative Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

3. Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.

4. Data Science Center, Promotion Unit, Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital, Sapporo, Japan.

5. Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osaka, Japan.

6. Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Funder

Takeda Pharmaceutical Company

Publisher

Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy

Subject

Obstetrics and Gynecology,Oncology,General Medicine

Link

https://ejgo.org/pdf/10.3802/jgo.2022.33.e55

Reference44 articles.

1. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

2. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

3. The evolving landscape of predictive biomarkers of response to PARP inhibitors

4. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

5. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthetic lethality from the combination of a histone methyltransferase, SUV39H2 inhibitor and a poly (ADP-ribose) polymerase inhibitor for uterine leiomyosarcoma;2024-02-07

2. Genomic Landscape of Endometrial, Ovarian, and Cervical Cancers in Japan from the Database in the Center for Cancer Genomics and Advanced Therapeutics;Cancers;2023-12-27

3. Genomic landscape of endometrial, ovarian and cervical cancers in Japan from database in the Center for Cancer Genomics and Advanced Therapeutics;2023-10-09

4. Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma;Gynecologic Oncology;2023-10

5. An Attempt to Develop a New Treatment Strategy for Rare Refractory Gynecological Malignancies: The Japanese Gynecologic Oncology Group;JMA Journal;2023